JPMorgan Chase & Co. Lowers Repligen (NASDAQ:RGEN) Price Target to $200.00

Repligen (NASDAQ:RGEN) had its price target dropped by analysts at JPMorgan Chase & Co. from $230.00 to $200.00 in a report issued on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 19.72% from the stock’s previous close.

RGEN has been the subject of a number of other research reports. Stifel Nicolaus boosted their price target on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. KeyCorp upped their target price on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $197.75.

Repligen Price Performance

Shares of NASDAQ:RGEN traded up $0.74 during trading on Thursday, reaching $167.05. 454,984 shares of the company traded hands, compared to its average volume of 538,521. The company’s 50 day moving average is $180.81 and its two-hundred day moving average is $173.90. The firm has a market capitalization of $9.33 billion, a PE ratio of 668.23, a PEG ratio of 5.44 and a beta of 1.03. The company has a quick ratio of 5.75, a current ratio of 6.35 and a debt-to-equity ratio of 0.26. Repligen has a 52 week low of $110.45 and a 52 week high of $211.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. During the same period last year, the firm posted $0.64 EPS. Repligen’s quarterly revenue was down 17.1% on a year-over-year basis. As a group, sell-side analysts predict that Repligen will post 1.46 earnings per share for the current year.

Insider Buying and Selling at Repligen

In related news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now owns 24,260 shares in the company, valued at approximately $4,699,889.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Repligen news, CEO Anthony Hunt sold 16,707 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the transaction, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the transaction, the vice president now owns 24,260 shares in the company, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 25,597 shares of company stock worth $5,039,532. Insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Repligen by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 5,078,294 shares of the biotechnology company’s stock worth $913,077,000 after acquiring an additional 33,404 shares in the last quarter. Artisan Partners Limited Partnership raised its stake in shares of Repligen by 11.3% in the third quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company’s stock worth $247,558,000 after purchasing an additional 157,807 shares during the last quarter. Brown Capital Management LLC raised its stake in shares of Repligen by 5.8% in the fourth quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock worth $274,207,000 after purchasing an additional 83,416 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Repligen by 2.1% in the third quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company’s stock worth $222,075,000 after purchasing an additional 29,215 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Repligen by 13.0% in the third quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company’s stock worth $190,117,000 after purchasing an additional 137,220 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.